The UAE Covid vaccine could become a global leader, but we must see full data | Sophie Zinser

China and the Emirates have teamed up to launch a rebranded vaccine – and that’s good news for the developing world

China’s leading vaccine just got rebranded. On Sunday 28 March, its major pharmaceutical company, Sinopharm, announced a new joint venture with G42, a UAE-based tech company: the vaccine is called Hayat-Vax, hayat meaning “life” in Arabic. The partnership shows immense promise as a new source of vaccines across the developing world.

But there’s a catch: a lack of scientific transparency in its phase III clinical trial data. A successful phase III trial is the golden seal confirming a jab’s efficacy once and for all. It allows scientists to observe possible side effects and make comparisons with placebo cases, while mirroring real-life conditions. From a scientific perspective, it provides critical evidence for developing future vaccines. But Hayat-Vax’s phase III data hasn’t been released.

Continue reading...

Coronavirus | The Guardian

Comments

Popular posts from this blog

Omicron could overwhelm NHS if it is as virulent as Delta, Neil Ferguson says

Ministers accused of sowing confusion over England’s travel advice

VAT: from Covid tests to child car seats, there are calls to ‘scrap the tax’